Research Antibodies & Reagents Market: Growth, Size, Share, and Trends

Market Growth Outlook Summary

The global research antibodies & reagents market growth forecasted to transform from USD 11.8 billion in 2023 to USD 16.2 billion by 2028, driven by a CAGR of 6.5%. An increase in research activity&mdash largely drives the growth of the research antibodies and reagents market;especially in the life sciences industry—along with growing industry-academia collaborations are a primary growth driver for this market. There is also an increasing emphasis on custom antibody development via CROs. Additionally, the high growth potential in emerging economies and the rising demand for personalized therapeutics and protein requirements are expected to offer significant growth opportunities for players. On the other hand, complexities associated with antibody development and increasing pricing pressure are challenges expected to hinder market growth to a certain extent.

Research Antibodies and Reagents Market- Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

Research antibodies & Reagents Market Dynamics

DRIVER: Rising funding for life science research

The R&D sector has conventionally remained capital-intensive due to long development periods and approval cycles. R&D investments occupy a prime position in global expenditure. Governments recognize R&D as a crucial aspect of a nation’s progress, international competitiveness, and public benefit. Due to this, R&D expenditure and funding have witnessed a steady increase over the years. According to CBRE Research, R&D expenditures by US life sciences companies have grown by ~ 40% over the past five years to reach nearly USD 154 billion in 2021. In the last two decades, antibodies have reformed the pharmaceutical industry landscape, and today, they are amongst the fastest-growing and most lucrative in therapeutics. As of 2022, five out of the top ten globally best-selling drugs are antibody-based, such as Humira (adalimumab), Keytruda (pembrolizumab), Stelara (ustekinumab), and Opdivo (nivolumab). The rising demand for efficient therapeutic monoclonal antibodies with fewer side effects has led to the growing focus on the R&D of biopharmaceuticals, which creates a high need for research antibodies and reagents.

RESTRAINT: Quality concerns and inadequacy of reproducible results

Variations in antibody production techniques have resulted in a lack of reproducibility of results. There are no standards for their validation nor agreed-upon definitions of reproducibility across all antibody offerings. The lot-to-lot variability of these antibodies significantly affects the results of basic research and clinical screening tests. According to an article in the Journal of Analytical Chemistry Insights, companies such as Amgen and Bayer HealthCare were unable to reproduce the most-examined landmark papers in their field. Thus, variations in the quality of antibodies are a major driver of what has been deemed a reproducibility crisis—a growing realization that the results of many biomedical experiments cannot be reproduced and that conclusions based on them may be unfounded. With the growing focus on antibody quality, research reproducibility, and technological advancements, vendors need to offer higher-quality products in the market.

OPPORTUNITY: High-growth potential of emerging economies

The Asia Pacific region has high potential and offers growth opportunities to research antibodies and reagnets market players as in forecoming period as the region has a diversified healthcare market in this region, the infectious and chronic diseases incidence rate is growing, Also, there are significant R&D fundings for genomics and proteomincs projects. The countries such as China, Brazil, & India have seen focus on proteomics projects. In these countries, proteomics research mainly focuses on the use of antibody-based proteomics involving the generation of protein-specific antibodies to functionally explore the human proteome and determine the mechanism of action of drugs. The significant growth opportunities offered by emerging countries such as China, India, and Indonesia can be attributed to the high growth in their respective pharmaceutical & biopharmaceutical sectors due to the presence of less stringent regulatory policies and low-cost and skilled labor. Owing to cost advantages and skilled labor, these countries are a hub for bioprocess outsourcing.

CHALLENGE: Complexities associated with antibody development

The development of monoclonal or polyclonal antibodies is a time-intensive and complex procedure, as it requires specific considerations such as the antigen against which antibodies need to be generated, specificity & sensitivity, and reproducibility. Besides, the technologies required for antibody production include large bioreactors, chromatography resins, filtration systems, and media and buffers for upstream processing, downstream processing, and purification. Such operations require high capital investment, making the entire procedure cost-intensive. Research antibody manufacturing can also be a time-consuming process, taking several months or even years to complete. This can be a challenge for researchers who need antibodies quickly for their research. Proper validation of antibodies is essential but can be challenging. Validating antibodies for specific applications and ensuring they target the intended protein can be time-consuming. Moreover, the average time required for the development of a particular mAb is over five months. Thus, although antibody and reagent production has seen significant advances in recent years, the requirement of high capital investments and time constraints can potentially hamper market growth to a certain extent.

Global Research antibodies & Reagents Market: Supply Chain Analysis

The research antibodies and reagents market supply chain comprise of manufacturers, distributors (involved in the supply of these products), and end customers (pharmaceutical & biotechnology companies, research laboratories, and CROs) are the key stakeholders in the supply chain of the research antibodies and reagents market. On the other hand, academic researchers, investors/funders, and health regulatory bodies are the primary influencers in this market.

Research laboratories held a dominant share in end user segment in research antibodies & reagents industry.

Based on the end user, the global research antibodies & reagents market is categorized into research laboratories, pharmaceutical & biotechnology companies, and contract research organizations (CROs). Research laboratories segment accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising research grants, growing industry-academia collaborations for biomedical & life sciences research, and growing government funding investments for academic and research institutions.

The proteomics segment is expected to register the largest share in application segment in research antibodies & reagents industry during the forecast period.

Based on the application, the research antibodies & reagents market is segmented into proteomics, genomics, and drug development. In 2022, the proteomics segment accounted for the largest share. The large share of this segment is attributed to the high deployment of proteomics-based approaches in disease profiling, increasing government funding, rising demand for personalized and protein therapeutics, and increasing R&D expenditure.

To know about the assumptions considered for the study, download the pdf brochure

North America accounted for largest share in Research antibodies & reagents industry in 2022.

Geographically, the Research antibodies and reagents market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held dominant share followed by Europe. Increasing investments in the development of structure-based drug designs; growing research in genomics and proteomics; the rising demand for high-quality research tools for data reproducibility; and the focus of stakeholders on research projects involving proteins, associated biomolecules, and genes are the key factors driving the North American market.

Key players in the global research antibodies & reagents market include Abcam plc (UK), Cell Signaling Technology, Inc. (US), Thermo Fisher Scientific Inc (US), Merck KGaA (Germany), BD (US), Bio-Rad Laboratories Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies(US), Danaher Corporation (US), Lonza (Switzerland), GenScript (China), Revvity (US), SouthernBiotech (US),& Illumina(US), ImmunoPrecise Antibodies Ltd (US), Fujirebio (Sweden), Analytik Jena GmbH+Co. KG (Germany), Omega Bio-tek, Inc. (US), Dovetail Genomics (US), Atlas Antibodies (Sweden), Rockland Immunochemicals, Inc. (US), Santa Cruz Biotechnology, Inc.(US), Jackson ImmunoResearch Inc. (US), Proteintech Group, Inc. (US), and ICL, Inc. (US).

Scope of the Research Antibodies & Reagents Industry:

The study categorizes the Research Antibodies & Reagents Market to forecast revenue and analyze trends in each of the following submarkets

By Product

• Reagent
  • Media & Sera
  • Stains & Dyes
  • Fixatives
  • Buffers
  • Solvents
  • Enzymes
  • Probes
  • Other Reagents
• Antibodies
  • By Type
    • Primary Antibodies
    • Secondary Antibodies
  • By Form
    • Monoclonal
    • Polyclonal
    • Recombinant
  • By Source
    • Mice
    • Rabbits
    • Other Sources
  • By Research Area
    • Oncology
    • Infectious Diseases
    • Immunology
    • Neurobiology
    • Stem Cells
    • Other Research Areas

By Technology

• Western Blotting
• Flow Cytometry
• Enzyme-linked immunosorbent assay (ELISA)
• Immunohistochemistry
• Immunofluorescence
• Immunoprecipitation
• Other Technologies

By Application

• Proteomics
• Drug Development
• Genomics

By End User

• Pharmaceutical & Biotechnologies Industries
• Academic & Research Institutions
• Contract Research Organizations

By region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • RoLATAM
• Middle East & Africa
  • Middle East
  • Africa

Recent Developments of Research Antibodies & Reagents Industry

• In August 2023, Danaher (US) entered into a definitive agreement to acquire all the outstanding shares of Abcam plc (UK). Through this development, Abcam is expected to operate as a standalone operating company within Danaher’s Life Sciences segment.
• In August 2023, Agilent Technologies, Inc. (US) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia. The facility is focused on building local capabilities to accelerate research and development (R&D) in life science research.
• In June 2023, Cell Signaling Technology, Inc. (US) and Lunaphore Technologies SA (Switzerland) have decided to partner to integrate CST antibodies into Lunaphore's COMET platform for Spatial Biology research.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst